Skip to main content
TipRanks
Go Ultimate75% OFF

Codexis (4QK) AI Stock Analysis

0 Followers
DE:4QK

Codexis

(Frankfurt:4QK)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue and Product GrowthStrong recent revenue and product-sales growth indicates improving commercial traction across Codexis’s pharma biocatalysis business. Continued adoption of proprietary enzymes can expand recurring supply opportunities, strengthen customer relationships, and support a more durable revenue base.
Negative Factors
Persistent Net LossesCodexis remains loss-making even after a substantial year-over-year improvement, showing that strong gross margins have not yet translated into sustainable earnings. Continued losses could constrain reinvestment capacity and leave the business dependent on operating improvements or external financing.

Codexis (4QK) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%DE:4QK-30.43%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 116.17M
Dividend Yield
―
Average Volume (3M)
1,533
Price to Earnings (P/E)
-5.4
Beta (1Y)
0.93
Revenue Growth
57.86%
EPS Growth
75.05%
Country
Germany
Employees
146
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Codexis Business Overview & Revenue Model

Company Description

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemi...

Codexis Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:12.65%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Highlights included substantial revenue growth, improving gross margins, lower operating expenses, improved biocatalysis product sales, progress to 100-gram ECO Synthesis scale, three to fourfold higher potency in stereocontrolled siRNA, growing customer and CDMO engagement, and a cash runway expected through 2028. The main negatives were the continuing net loss, a lower cash balance versus year-end 2025, the remaining work required to reach larger-scale manufacturing, and uncertain timing for additional commercial agreements.

Positive Updates

Strong Third-Quarter Revenue Performance
Third-quarter 2026 revenue was $19.3 million, compared with $8.6 million in the third quarter of 2025. Management described this as the fourth consecutive quarterly on-target performance, driven by strong performance in the pharma biocatalysis business.

Negative Updates

Company Remains Loss-Making
Net loss for the third quarter of 2026 was $8.1 million, although this improved from a $19.6 million loss in the third quarter of 2025.

Company Guidance

Codexis reiterated its 2026 top line guidance, expecting revenue in the range of $72 million to $76 million, and now anticipates achieving gross margins in the low 70s for the full year 2026; the company expects that its current cash will be sufficient to fund planned operations and capital expenditures through 2028, in line with previous cash runway guidance, and said it will be moving toward 500-gram production scale, advancing the ECO Synthesis raw material supply chain, and beginning construction on its GMP production facility.

Codexis Risk Analysis

Codexis disclosed 50 risk factors in its most recent earnings report. Codexis reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.Our business may be affected by the evolving regulatory framework for AI TechnologiesQ4, 2025
2.International trade policies, including tariffs, sanctions and trade barriers, may adversely affect our business.Q4, 2025

Codexis Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:4QK against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CGENCGEN66Neutral$193.24M5.2639.30%―999.97%―
DTILDTIL54Neutral$203.37M-5.97-58.09%―6353.01%84.80%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MXCTMXCT50Neutral$121.84M-4.52-17.24%―-0.13%38.72%
CBUSCBUS45Neutral$91.71M-0.78-581.53%―19.45%53.78%
ADAGADAG41Neutral$107.43M-3.14-29.09%―8906.15%41.48%

* Healthcare Sector Average

Performance Comparison

0%100%200%DE:4QKCGENMXCTCBUSDTILADAGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:4QK and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:4QKCodexis0.94-0.45-32.18%
CGENCompugen2.020.4226.25%
MXCTMaxCyte, Inc.1.17-0.53-31.18%
CBUSCibus, Inc.1.390.129.45%
DTILPrecision Biosciences7.052.2346.27%
ADAGAdagene, Inc.1.48-0.33-18.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.